Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free ANAB Stock Alerts

AnaptysBio (ANAB) Financials

AnaptysBio logo
$62.21 -5.15 (-7.65%)
As of 01:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for AnaptysBio

Annual Income Statements for AnaptysBio

This table shows AnaptysBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.41 -4.26 -30 -62 -97 -20 -58 -129 -164 -145 -13
Consolidated Net Income / (Loss)		 -5.41 -4.26 -30 -62 -97 -20 -58 -129 -164 -145 -13
Net Income / (Loss) Continuing Operations		 -5.41 -4.26 -30 -62 -97 -20 -58 -129 -164 -145 -13
Total Pre-Tax Income 		-5.27 -4.26 -30 -62 -97 -20 -58 -129 -164 -145 -13
Total Operating Income		 -3.32 -3.03 -29 -67 -107 -24 -57 -115 -164 -115 48
Total Gross Profit		 18 17 10 5.00 8.00 75 63 10 17 91 235
Total Revenue		 18 17 10 5.00 8.00 75 63 10 17 91 235
Operating Revenue		 18 17 10 5.00 8.00 75 63 10 17 91 235
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 21 20 39 72 115 99 120 125 182 206 187
Selling, General & Admin Expense		 3.59 4.29 9.34 16 16 19 21 37 42 42 51
Research & Development Expense		 17 15 29 56 99 80 98 89 140 164 136
Total Other Income / (Expense), net		 -1.94 -1.23 -1.29 4.87 9.94 3.95 -0.98 -14 0.79 -30 -61
Interest Expense		 0.46 0.46 1.78 1.65 1.04 0.00 1.45 21 18 50 80
Interest & Investment Income		 0.02 0.13 1.62 6.69 11 3.96 0.43 7.55 19 20 13
Other Income / (Expense), net		 -1.50 -0.90 -1.14 -0.16 0.00 -0.01 0.04 0.01 -0.00 0.01 5.43
Income Tax Expense		 0.14 0.00 0.00 -0.19 -0.15 0.00 0.00 0.02 -0.00 0.00 0.16
Basic Earnings per Share		 ($2.12) ($1.62) ($1.52) ($2.50) ($3.60) ($0.73) ($2.11) ($4.57) ($6.08) ($5.12) ($0.46)
Weighted Average Basic Shares Outstanding		 2.55M 2.64M 19.78M 24.67M 27.06M 27.30M 27.43M 28.17M 26.92M 28.38M 28.76M
Diluted Earnings per Share		 ($2.12) ($1.62) ($1.52) ($2.50) ($3.60) ($0.73) ($2.11) ($4.57) ($6.08) ($5.12) ($0.46)
Weighted Average Diluted Shares Outstanding		 2.55M 2.64M 19.78M 24.67M 27.06M 27.30M 27.43M 28.17M 26.92M 28.38M 28.76M
Weighted Average Basic & Diluted Shares Outstanding		 2.55M 2.64M 19.78M 24.67M 27.06M 27.30M 27.67M 27.93M 26.76M 30.67M 28.75M

Quarterly Income Statements for AnaptysBio

This table shows AnaptysBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -40 -37 -42 -44 -47 -33 -22 -39 -39 15 50
Consolidated Net Income / (Loss)		 -40 -37 -42 -44 -47 -33 -22 -39 -39 15 50
Net Income / (Loss) Continuing Operations		 -40 -37 -42 -44 -47 -33 -22 -39 -39 15 50
Total Pre-Tax Income 		-40 -37 -42 -44 -47 -33 -22 -39 -39 15 50
Total Operating Income		 -40 -38 -42 -42 -40 -23 -9.67 -28 -26 35 67
Total Gross Profit		 3.46 3.32 9.01 7.18 11 30 43 28 22 76 108
Total Revenue		 3.46 3.32 9.01 7.18 11 30 43 28 22 76 108
Operating Revenue		 3.46 3.32 9.01 7.18 11 30 43 28 22 76 108
Total Operating Expenses		 44 41 51 49 51 53 53 55 48 42 41
Selling, General & Admin Expense		 11 10 10 12 9.30 11 10 14 11 10 16
Research & Development Expense		 33 31 41 37 42 42 43 41 38 31 26
Total Other Income / (Expense), net		 0.30 0.42 -0.08 -1.74 -6.33 -10 -12 -12 -12 -20 -17
Interest Expense		 4.36 4.43 4.96 6.32 11 15 17 18 20 23 20
Interest & Investment Income		 4.65 4.85 4.88 4.58 4.62 5.32 5.26 4.41 3.65 2.92 2.51
Other Income / (Expense), net		 0.00 0.00 -0.00 -0.00 0.00 -0.01 0.02 1.90 3.53 0.00 -0.00
Income Tax Expense		 0.00 0.00 - 0.00 0.01 0.00 - 0.04 0.04 0.00 0.08
Basic Earnings per Share		 ($1.50) ($1.41) ($1.59) ($1.64) ($1.71) ($1.14) ($0.63) ($1.28) ($1.34) $0.54 $1.62
Weighted Average Basic Shares Outstanding		 26.63M 26.55M 26.92M 26.80M 27.36M 28.89M 28.38M 30.64M 28.81M 27.83M 28.76M
Diluted Earnings per Share		 ($1.50) ($1.41) ($1.59) ($1.64) ($1.71) ($1.14) ($0.63) ($1.28) ($1.34) $0.52 $1.64
Weighted Average Diluted Shares Outstanding		 26.63M 26.55M 26.92M 26.80M 27.36M 28.89M 28.38M 30.64M 28.81M 29.02M 28.76M
Weighted Average Basic & Diluted Shares Outstanding		 26.55M 26.58M 26.76M 27.32M 27.45M 30.43M 30.67M 29.38M 28.00M 27.69M 28.75M

Annual Cash Flow Statements for AnaptysBio

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 29 -0.45 30 32 57 79 245 -424 -35 87 115
Net Cash From Operating Activities		 -9.69 -9.03 -19 -49 -70 -14 -46 -74 -121 -135 20
Net Cash From Continuing Operating Activities		 -9.69 -9.03 -19 -49 -70 -14 -46 -74 -121 -135 20
Net Income / (Loss) Continuing Operations		 -5.41 -4.26 -30 -62 -97 -20 -58 -129 -164 -145 -13
Consolidated Net Income / (Loss)		 -5.41 -4.26 -30 -62 -97 -20 -58 -129 -164 -145 -13
Depreciation Expense		 0.27 0.23 0.18 0.32 0.51 0.56 0.62 0.68 0.65 0.61 0.56
Amortization Expense		 - - 0.01 -1.23 0.89 1.06 1.47 1.66 1.72 1.79 1.86
Non-Cash Adjustments To Reconcile Net Income		 1.99 2.02 7.59 11 10 12 16 45 35 38 118
Changes in Operating Assets and Liabilities, net		 -6.56 -7.03 2.85 3.46 16 -7.83 -6.61 7.38 5.11 -31 -88
Net Cash From Investing Activities		 -0.24 -0.05 -243 -142 131 94 39 -395 145 95 228
Net Cash From Continuing Investing Activities		 -0.24 -0.05 -243 -142 131 94 39 -395 145 95 228
Purchase of Property, Plant & Equipment		 -0.24 -0.05 -0.29 -1.06 -0.81 -0.57 -1.37 -0.36 -0.81 -0.36 -0.09
Purchase of Investments		 0.00 0.00 -291 -348 -252 -195 -119 -803 -304 -380 -196
Sale and/or Maturity of Investments		 0.00 0.00 48 206 384 290 159 408 449 476 425
Net Cash From Financing Activities		 39 8.63 292 223 -4.49 -0.88 252 44 -59 127 -133
Net Cash From Continuing Financing Activities		 39 8.63 292 223 -4.49 -0.88 252 44 -59 127 -133
Repurchase of Common Equity		 -1.45 -1.15 - -0.18 - - 0.00 0.00 -50 -0.46 -69
Issuance of Common Equity		 0.00 0.00 294 227 3.01 0.50 2.55 12 2.47 100 14
Other Financing Activities, net		 0.16 0.03 1.52 2.95 0.00 0.00 250 32 -12 27 -78
Cash Interest Paid		 0.33 0.35 1.09 1.04 0.42 0.00 - 0.00 0.00 42 80

Quarterly Cash Flow Statements for AnaptysBio

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -59 -8.91 9.67 18 18 120 -69 -24 -54 66 128
Net Cash From Operating Activities		 -25 -36 -34 -37 -21 -10 -67 -11 -40 -27 98
Net Cash From Continuing Operating Activities		 -25 -36 -34 -37 -21 -10 -67 -11 -40 -27 98
Net Income / (Loss) Continuing Operations		 -40 -37 -42 -44 -47 -33 -22 -39 -39 15 50
Consolidated Net Income / (Loss)		 -40 -37 -42 -44 -47 -33 -22 -39 -39 15 50
Depreciation Expense		 0.16 0.16 0.17 0.16 0.15 0.14 0.15 0.15 0.14 0.14 0.13
Amortization Expense		 0.42 0.43 0.44 0.44 0.44 0.45 0.46 0.46 0.46 0.47 0.48
Non-Cash Adjustments To Reconcile Net Income		 8.94 9.16 6.33 13 14 18 -5.28 48 24 -24 70
Changes in Operating Assets and Liabilities, net		 4.91 -8.92 0.93 -7.16 11 4.32 -40 -20 -26 -19 -22
Net Cash From Investing Activities		 -20 31 49 69 -2.44 59 -29 15 36 103 74
Net Cash From Continuing Investing Activities		 -20 31 49 69 -2.44 59 -29 15 36 103 74
Purchase of Property, Plant & Equipment		 -0.19 -0.16 -0.28 -0.03 -0.03 -0.04 -0.26 -0.04 -0.04 -0.01 -0.00
Sale and/or Maturity of Investments		 99 101 116 128 147 110 92 137 91 123 74
Net Cash From Financing Activities		 -13 -3.07 -5.16 -14 42 71 28 -29 -50 -10 -43
Net Cash From Continuing Financing Activities		 -13 -3.07 -5.16 -14 42 71 28 -29 -50 -10 -43
Repurchase of Common Equity		 -12 - - 0.00 - -0.37 -0.58 -4.42 -51 -9.72 -3.38
Issuance of Common Equity		 0.78 0.16 0.26 0.81 0.98 4.13 0.56 0.29 1.42 0.34 12
Other Financing Activities, net		 -1.80 -3.23 -5.47 -14 41 68 27 -24 -0.82 -1.01 -52
Cash Interest Paid		 - - - 0.00 - - - 18 18 21 23

Annual Balance Sheets for AnaptysBio

This table presents AnaptysBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 62 329 509 435 417 643 610 452 484 364
Total Current Assets		 58 253 434 378 397 554 447 407 432 350
Cash & Equivalents		 51 81 114 171 250 496 71 36 123 238
Short-Term Investments		 0.00 167 313 203 143 52 370 355 262 73
Accounts Receivable		 1.23 - - - 0.00 0.88 1.42 6.85 41 34
Prepaid Expenses		 1.63 2.69 6.96 3.51 2.91 4.90 4.55 9.08 5.74 4.76
Plant, Property, & Equipment, net		 0.47 0.67 1.45 1.62 1.78 2.28 2.09 2.10 1.85 1.37
Total Noncurrent Assets		 3.50 76 73 56 18 87 161 43 50 13
Long-Term Investments		 0.00 76 73 54 18 67 143 27 35 0.00
Other Noncurrent Operating Assets		 3.44 0.05 0.15 1.48 0.60 20 18 16 15 13
Total Liabilities & Shareholders' Equity		 62 329 509 435 417 643 610 452 484 364
Total Liabilities		 23 22 23 30 20 287 348 364 413 327
Total Current Liabilities		 5.71 14 22 30 20 16 26 37 45 39
Accounts Payable		 2.28 2.32 5.44 16 4.22 1.74 2.78 4.70 4.00 3.87
Accrued Expenses		 3.43 4.88 8.76 11 15 13 22 31 40 33
Other Current Liabilities		 0.00 0.02 0.06 0.87 0.34 1.51 1.64 1.78 1.93 2.08
Total Noncurrent Liabilities		 17 7.69 0.80 0.65 0.00 271 322 327 368 289
Other Noncurrent Operating Liabilities		 3.24 - 0.80 0.65 0.00 271 322 327 368 289
Total Equity & Noncontrolling Interests		 -38 308 486 405 397 356 262 88 71 37
Total Preferred & Common Equity		 -38 308 486 405 397 356 262 88 71 37
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -38 308 486 405 397 356 262 88 71 37
Common Stock		 17 393 633 649 661 679 718 703 830 810
Retained Earnings		 -55 -85 -147 -244 -264 -322 -450 -614 -759 -773
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.43 -0.22 0.34 -0.00 -0.42 -5.25 -0.80 0.31 -0.02

Quarterly Balance Sheets for AnaptysBio

This table presents AnaptysBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 619 552 517 487 406 427 493 422 335 353
Total Current Assets		 450 437 439 428 372 367 449 363 292 331
Cash & Equivalents		 59 95 35 26 54 72 192 99 44 110
Short-Term Investments		 384 337 394 387 301 279 239 241 221 139
Accounts Receivable		 1.18 1.52 3.18 3.27 7.09 9.01 12 18 21 76
Prepaid Expenses		 6.30 4.48 5.87 12 11 7.54 6.37 5.29 4.78 6.01
Plant, Property, & Equipment, net		 1.97 1.98 2.02 2.25 1.95 1.83 1.73 1.74 1.63 1.50
Total Noncurrent Assets		 166 113 77 57 31 58 43 57 42 21
Long-Term Investments		 148 95 59 40 15 43 28 43 28 7.70
Other Noncurrent Operating Assets		 19 18 17 17 16 16 15 14 14 13
Total Liabilities & Shareholders' Equity		 619 552 517 487 406 427 493 422 335 353
Total Liabilities		 341 361 369 367 358 417 409 388 380 383
Total Current Liabilities		 21 36 42 39 32 40 44 44 36 38
Accounts Payable		 3.01 3.17 4.76 6.52 4.58 4.89 3.59 6.12 3.33 2.89
Accrued Expenses		 16 31 35 31 26 34 38 36 30 33
Other Current Liabilities		 1.60 1.67 1.71 1.74 1.81 1.85 1.89 1.96 2.00 2.04
Total Noncurrent Liabilities		 320 325 327 328 326 377 365 344 344 344
Other Noncurrent Operating Liabilities		 320 325 327 328 326 377 365 344 344 344
Total Equity & Noncontrolling Interests		 278 191 148 120 48 9.88 84 34 -45 -29
Total Preferred & Common Equity		 278 191 148 120 48 9.88 84 34 -45 -29
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 278 191 148 120 48 9.88 84 34 -45 -29
Common Stock		 708 689 687 695 706 715 821 833 793 793
Retained Earnings		 -424 -495 -535 -572 -658 -705 -738 -799 -837 -822
Accumulated Other Comprehensive Income / (Loss)		 -6.01 -3.27 -3.61 -2.35 -0.62 -0.42 0.76 0.16 -0.01 0.05

Annual Metrics And Ratios for AnaptysBio

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 27,688,470.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 27,688,470.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.48
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -2.33 -2.12 -20 -47 -75 -17 -40 -81 -115 -80 34
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -30.75% -130.63% -113.54% 90.10%
Earnings before Interest and Taxes (EBIT)		 -4.82 -3.93 -30 -67 -107 -24 -57 -115 -164 -115 53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.55 -3.70 -30 -68 -106 -22 -55 -113 -162 -113 56
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -3.90 -16 -43 -59 -24 204 -17 -107 -60 -42
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 1.79 -2.36 -6.33 -22 -15 -259 -322 -330 -350 -274
Increase / (Decrease) in Invested Capital		 0.00 1.79 -4.14 -3.98 -16 7.68 -244 -63 -7.75 -20 76
Book Value per Share		 $0.00 ($14.50) $13.09 $18.18 $14.93 $14.51 $12.96 $9.22 $3.32 $2.33 $1.34
Tangible Book Value per Share		 $0.00 ($14.50) $13.09 $18.18 $14.93 $14.51 $12.96 $9.22 $3.32 $2.33 $1.34
Total Capital		 0.00 53 322 494 406 397 356 262 88 71 37
Total Debt		 0.00 14 14 7.57 1.38 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 14 7.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -37 -310 -493 -427 -411 -615 -584 -418 -421 -312
Capital Expenditures (CapEx)		 0.24 0.05 0.29 1.06 0.81 0.57 1.35 0.36 0.81 0.36 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 1.27 -2.93 -7.13 -25 -17 -10 -20 -22 1.08 -0.01
Debt-free Net Working Capital (DFNWC)		 0.00 53 245 420 350 377 538 421 369 386 312
Net Working Capital (NWC)		 0.00 53 239 412 348 377 538 421 369 386 312
Net Nonoperating Expense (NNE)		 3.08 2.14 9.92 15 22 3.22 18 48 49 65 47
Net Nonoperating Obligations (NNO)		 0.00 -37 -310 -493 -427 -411 -615 -584 -418 -421 -312
Total Depreciation and Amortization (D&A)		 0.27 0.23 0.19 -0.92 1.41 1.62 2.09 2.34 2.38 2.40 2.42
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.12) ($1.62) ($1.52) ($2.50) ($3.60) ($0.73) ($2.11) ($4.57) ($6.08) ($5.12) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 2.55M 2.64M 23.81M 26.99M 27.27M 27.37M 27.43M 28.17M 26.92M 28.38M 28.76M
Adjusted Diluted Earnings per Share		 ($2.12) ($1.62) ($1.52) ($2.50) ($3.60) ($0.73) ($2.11) ($4.57) ($6.08) ($5.12) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 2.55M 2.64M 23.81M 26.99M 27.27M 27.37M 27.43M 28.17M 26.92M 28.38M 28.76M
Adjusted Basic & Diluted Earnings per Share		 ($2.12) ($1.62) ($1.52) ($2.50) ($3.60) ($0.73) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.55M 2.64M 19.78M 24.67M 27.06M 27.30M 27.67M 27.93M 26.76M 30.67M 28.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.33 -2.12 -20 -47 -75 -17 -40 -81 -115 -80 34
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for AnaptysBio

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 27,688,470.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 27,688,470.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.79
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -28 -26 -29 -30 -28 -16 -6.77 -19 -18 35 67
Return On Investment Capital (ROIC_SIMPLE)		 - - -33.48% - - - -9.55% -56.66% 40.95% -117.98% 179.50%
Earnings before Interest and Taxes (EBIT)		 -40 -38 -42 -42 -40 -23 -9.65 -26 -23 35 67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -37 -42 -42 -40 -22 -9.05 -25 -22 35 68
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 44 -6.40 -22 -42 15 25 13 7.30 -63 -53 -8.76
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -340 -333 -330 -322 -384 -374 -350 -349 -338 -286 -274
Increase / (Decrease) in Invested Capital		 -72 -20 -7.75 13 -43 -41 -20 -27 45 88 76
Book Value per Share		 $5.60 $4.54 $3.32 $1.79 $0.36 $3.07 $2.33 $1.11 ($1.52) ($1.05) $1.34
Tangible Book Value per Share		 $5.60 $4.54 $3.32 $1.79 $0.36 $3.07 $2.33 $1.11 ($1.52) ($1.05) $1.34
Total Capital		 148 120 88 48 9.88 84 71 34 -45 -29 37
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -489 -453 -418 -370 -393 -458 -421 -383 -294 -257 -312
Capital Expenditures (CapEx)		 0.19 0.16 0.28 0.03 0.03 0.04 0.26 0.04 0.04 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -33 -24 -22 -15 -24 -25 1.08 -21 -9.33 44 -0.01
Debt-free Net Working Capital (DFNWC)		 397 389 369 340 327 405 386 319 256 293 312
Net Working Capital (NWC)		 397 389 369 340 327 405 386 319 256 293 312
Net Nonoperating Expense (NNE)		 12 11 13 14 18 17 15 20 20 20 17
Net Nonoperating Obligations (NNO)		 -489 -453 -418 -370 -393 -458 -421 -383 -294 -257 -312
Total Depreciation and Amortization (D&A)		 0.59 0.59 0.60 0.61 0.60 0.60 0.60 0.61 0.60 0.61 0.61
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.50) ($1.41) ($1.59) ($1.64) ($1.71) ($1.14) ($0.63) ($1.28) ($1.34) $0.54 $1.62
Adjusted Weighted Average Basic Shares Outstanding		 26.63M 26.55M 26.92M 26.80M 27.36M 28.89M 28.38M 30.64M 28.81M 27.83M 28.76M
Adjusted Diluted Earnings per Share		 ($1.50) ($1.41) ($1.59) ($1.64) ($1.71) ($1.14) ($0.63) ($1.28) ($1.34) $0.52 $1.64
Adjusted Weighted Average Diluted Shares Outstanding		 26.63M 26.55M 26.92M 26.80M 27.36M 28.89M 28.38M 30.64M 28.81M 29.02M 28.76M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.55M 26.58M 26.76M 27.32M 27.45M 30.43M 30.67M 29.38M 28.00M 27.69M 28.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -26 -29 -30 -28 -16 -6.77 -19 -18 24 67
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Below is a concise, data-driven snapshot of AnaptysBio (ANAB) using the last four years of quarterly statements. The focus is on trends in revenue, profitability, cash flow, and balance-sheet strength that may matter to retail investors.

  • Q4 2025: Revenue (Operating Revenue) = 108,249,000; Net Income attributable to common shareholders = 49,614,000; Basic EPS = 1.62; Diluted EPS = 1.64.
  • Q4 2025: Strong cash generation — Net cash from continuing operating activities = 97,997,000; Net change in cash and equivalents = 128,363,000.
  • Q4 2025: Notable cash inflow from investing activities — Sale/maturity of investments = 73,501,000; Net cash from continuing investing activities = 73,500,000.
  • Q3 2025: Profitability resumes — Revenue = 76,320,000; Net income = 15,113,000; Basic EPS = 0.54; Diluted EPS = 0.52.
  • Across 2025, the company progressed from Q1–Q2 losses to Q3–Q4 profits, signaling a potential turning point in quarterly performance.
  • R&D and SG&A remain material cost lines (R&D in Q4 2025 = 25,559,000; SG&A = 15,789,000) with total operating expenses = 41,348,000, indicating ongoing pipeline investment that weighs on near-term margins.
  • Balance-sheet composition shows sizable liabilities vs. assets and ongoing equity deficits (as of Q3 2025: Total Liabilities ≈ 382.5M; Total Assets ≈ 353.1M; Retained Earnings ≈ -822.2M; Total Common Equity ≈ -29.4M).
  • Negative equity is persistent — cumulative losses have left retained earnings and total equity negative, implying ongoing capital erosion.
  • Near-term profitability and cash flow have shown volatility — Q1 2025 and Q2 2025 posted net losses (e.g., Q1 2025 net income = -39,329,000; Q2 2025 net income = -38,630,000) and cash from operating activities was negative in those quarters.
  • Investing/financing activity volatility — while Q4 2025 benefited from investment sales, other quarters show negative or mixed cash flows from investing and financing activities, highlighting uncertain short-term liquidity dynamics.
05/07/26 11:07 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About AnaptysBio's Financials

When does AnaptysBio's fiscal year end?

According to the most recent income statement we have on file, AnaptysBio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has AnaptysBio's net income changed over the last 10 years?

AnaptysBio's net income appears to be on an upward trend, with a most recent value of -$13.23 million in 2025, rising from -$5.41 million in 2015. The previous period was -$145.23 million in 2024. See AnaptysBio's forecast for analyst expectations on what’s next for the company.

What is AnaptysBio's operating income?
AnaptysBio's total operating income in 2025 was $47.90 million, based on the following breakdown:
  • Total Gross Profit: $234.60 million
  • Total Operating Expenses: $186.71 million
How has AnaptysBio's revenue changed over the last 10 years?

Over the last 10 years, AnaptysBio's total revenue changed from $17.57 million in 2015 to $234.60 million in 2025, a change of 1,235.2%.

How much debt does AnaptysBio have?

AnaptysBio's total liabilities were at $327.19 million at the end of 2025, a 20.8% decrease from 2024, and a 1,328.0% increase since 2016.

How much cash does AnaptysBio have?

In the past 9 years, AnaptysBio's cash and equivalents has ranged from $35.97 million in 2023 to $495.73 million in 2021, and is currently $238.20 million as of their latest financial filing in 2025.

How has AnaptysBio's book value per share changed over the last 10 years?

Over the last 10 years, AnaptysBio's book value per share changed from 0.00 in 2015 to 1.34 in 2025, a change of 134.4%.


Related Companies

Financial statements for NASDAQ:ANAB last updated on 3/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel